Nukkleus Inc. Files 8-K with SEC

TL;DR

NUKK filed an 8-K on 10/17/25. Check for updates.

AI Summary

Nukkleus Inc. filed an 8-K on October 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Brilliant Acquisition Corp., is incorporated in Delaware and headquartered in New York. This filing does not contain specific financial figures or transaction details.

Why It Matters

This 8-K filing indicates Nukkleus Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain specific negative or positive financial events.

Key Players & Entities

• Nukkleus Inc. (company) — Registrant
• Brilliant Acquisition Corp. (company) — Former company name
• October 17, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NUKK The Nasdaq
• $92.00 — sable for one Share of Common Stock for $92.00 per share NUKKW The Nasdaq Stock Ma

Filing Documents

• ea0261015-8k_nukkleus.htm (8-K) — 32KB
• ea026101501ex99-1_nukkleus.htm (EX-99.1) — 7KB
• ex99-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-099738.txt ( ) — 253KB
• nukk-20251017.xsd (EX-101.SCH) — 4KB
• nukk-20251017_def.xml (EX-101.DEF) — 26KB
• nukk-20251017_lab.xml (EX-101.LAB) — 36KB
• nukk-20251017_pre.xml (EX-101.PRE) — 25KB
• ea0261015-8k_nukkleus_htm.xml (XML) — 6KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 17, 2025, Nukkleus, Inc., (the "Company") issued a press release regarding the proposed initial public offering of units of SC II Acquisition Corp. I (the "SCII"), a newly formed special purpose acquisition company and indirect subsidiary of the Company. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. A registration statement, including a prospectus, which is preliminary and subject to completion, relating to the proposed offering has been filed with the Securities and Exchange Commission (the "SEC") but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration to buy these securities, nor shall there be any sales of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. When available, copies of the preliminary prospectus relating to the offering may be obtained from D. Boral Capital LLC: Attn: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at (212) 970-5150, or from the SEC's website at www.sec.gov. The information furnished under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Nukkleus, Inc. dated October 17, 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking to, statements regarding the anticipated size, timing, structure, and success of the proposed IPO of SC II, the expected composition of its sponsor and management team, and the prospects of completing a future business combination. There can be no assurance that the proposed offering of SC II will be completed on the terms described herein, within the expected timeframe, or at all. The completion of the proposed offering and the subsequent business-combination process remain subject to market, legal, and regulatory conditions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUKKLEUS INC. Date: October 17, 2025 By: /s/ Menachem Shalom Name: Menachem Shalom Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR